Abstract
Fabry disease is an X-linked inherited lysosomal storage disorder caused by an inborn deficiency of the enzyme α-galactosidase A. Enzyme replacement therapy (ERT) with agalsidase alpha or beta isozymes is an effective treatment. Cross-reactivity of immunoglobulin G (IgG) antibodies with agalsidase alpha and beta has been reported, but no such reaction has been recorded for IgE antibodies. We present the case of a patient with Fabry disease who developed antiagalsidase beta IgE antibodies without cross-reactivity to agalsidase alpha. A 17-year-old boy with Fabry disease had suffered from severe atopic dermatitis since infancy, and he complained for several years of peripheral pain during the summer months and when exercising. Fabry disease was confirmed by family history and a positive enzyme test, and ERT was commenced. Following infusion of agalsidase beta (1.0 mg/kg), the patient complained of a high temperature in his hands and feet, and purulent eczema developed. The infusion dose was reduced to 0.2 mg/kg, but the hyperthermia did not change, although its duration decreased. After three infusions, eosinophilia developed (9.4%; 573 cells/μl blood) and remained unresolved after four infusions with agalsidase beta. Treatment with this enzyme was discontinued, and agalsidase alpha (0.2 mg/kg) started. This produced immediate resolution of the eosinophilia, which has been maintained during follow-up. In conclusion, this patient developed IgE antibodies against agalsidase beta, which demonstrated no cross-reactivity to agalsidase alpha. These findings emphasize the importance of analyzing IgE antibodies against both enzymes when patients exhibit severe infusion-related events.
Similar content being viewed by others
References
Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77–86
Bodensteiner D, Scott CR, Sims KB et al (2008) Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med 10:353–358
Eng CM, Guffon N, Wilcox WR et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345:9–16
Fabry H (2002) Angiokeratoma corporis diffusum- Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy. Acta Paediatr Suppl 91(439):3–5
Hoffman B (2009) Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring. Orphanet J Rare Dis 4:21
Keating GM, Simpson D (2007) Agalsidase Beta: a review of its use in the management of Fabry disease. Drugs 67:435–455
Lidove O, Joly D, Barbey F et al (2007) Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of the literature. Int J Clin Pract 61:293–302
Linhart A, Kampmann C, Zamorano JL et al (2007) Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 28:1228–1235
Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589–1595
MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38:750–760
Mehta A, Ginsberg L (2005) Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr 94(Suppl):9–10
Mehta A, Ricci R, Widmer U et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236–242
Moore DF, Kaneski CR, Askari H, Schiffmann R (2007) The cerebral vasculopathy of Fabry disease. J Neurol Sci 257:258–263
Nagueh SF (2003) Fabry disease. Heart 89:819–820
Pastores GM, Boyd E, Crandall K et al (2007) Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease. Nephrol Dial Transplant 22:1920–1925
Ramaswami U, Wendt S, Pintos-Morell G (2007) Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr 96:122–127
Schaefer E, Mehta A, Gal A (2005) Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome survey. Acta Paediatr Suppl 94(447):87–92
Schiffmann R, Ries M, Timmons M et al (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusión setting. Nephrol Dial Transplant 21:345–354
Tesmoingt C, Lidove O, Reberga A et al (2009) Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies. Br J Clin Pharmacol 68:765–769
Zarate YA, Hopkin RJ (2008) Fabry’s disease. Lancet 372:1427–1435
Acknowledgements
Editorial assistance was provided by Caroline McGown PhD, ContentEdNet, and sponsored by Shire Human Genetic Therapies and Dainippon Sumitomo Pharma.
Author information
Authors and Affiliations
Corresponding author
Additional information
Communicated by: Douglas A. Brooks
Competing interests: None declared.
Rights and permissions
About this article
Cite this article
Tanaka, A., Takeda, T., Hoshina, T. et al. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha. J Inherit Metab Dis 33 (Suppl 3), 249–252 (2010). https://doi.org/10.1007/s10545-010-9136-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10545-010-9136-0